What is the ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) chemotherapy regimen for Hodgkin lymphoma, including dosing schedule, number of cycles for different disease stages, and required monitoring?

ABVD Protocol for Hodgkin Lymphoma

ABVD chemotherapy consists of doxorubicin 25 mg/m², bleomycin 10 mg/m², vinblastine 6 mg/m², and dacarbazine 375 mg/m², all administered intravenously on days 1 and 15, with cycles repeated every 28 days. 1

Dosing Schedule

The standard ABVD regimen is administered as follows:

• Doxorubicin: 25 mg/m² IV on days 1 and 15
• Bleomycin: 10 mg/m² IV on days 1 and 15
• Vinblastine: 6 mg/m² IV on days 1 and 15
• Dacarbazine: 375 mg/m² IV on days 1 and 15
• Cycle length: 28 days (recycle on day 29) 1

Number of Cycles by Disease Stage

Limited-Stage Disease (Stage I-II Favorable)

Administer 2-3 cycles of ABVD followed by involved-site radiotherapy (ISRT) at 20 Gy. 1 This represents the standard of care for limited-stage disease with excellent disease control.

Intermediate-Stage Disease (Stage I-II Unfavorable)

Administer 4 cycles of ABVD followed by ISRT at 30 Gy. 1 This is widely considered standard of care for intermediate-stage disease.

Advanced-Stage Disease (Stage III-IV)

Administer 6 cycles of ABVD without radiotherapy in most cases. 1 Radiotherapy is reserved only for patients with PET-positive residual disease ≥2.5 cm after completing chemotherapy.

PET-Adapted Treatment Modifications

After 2 Cycles of ABVD:

• Negative interim PET (Deauville score 1-3):

  • Consider omitting bleomycin in cycles 3-6 (use AVD instead), especially in elderly patients or those at increased risk for lung toxicity 1
  • Complete planned total cycles without bleomycin

• Positive interim PET (Deauville score ≥3-4):

  • Switch to 2 cycles of BEACOPPescalated before proceeding to ISRT 1
  • This applies to both limited and intermediate-stage disease with significantly reduced relapse rates

Critical Age-Related Modifications

In patients >60 years old, bleomycin must be discontinued after the second cycle (2 cycles maximum) due to significantly increased pulmonary toxicity risk. 1 Continue with AVD (doxorubicin/vinblastine/dacarbazine) for remaining cycles.

Required Monitoring

Before Treatment Initiation:

• Cardiac function testing: Baseline echocardiogram or MUGA scan (doxorubicin cardiotoxicity risk) 1
• Pulmonary function tests: Baseline DLCO and spirometry (bleomycin pulmonary toxicity risk) 1
• Reproductive counseling: Offer sperm banking or oocyte/ovarian tissue cryopreservation before starting treatment 1

During Treatment:

• Bleomycin pulmonary toxicity monitoring:

  • Clinical assessment for dyspnea, cough, or pulmonary symptoms before each cycle
  • Consider discontinuing bleomycin if pulmonary symptoms develop
  • Total cumulative bleomycin dose should not exceed 400 units due to dose-related pulmonary toxicity 2

• Interim PET-CT: Perform after 2 cycles to guide treatment adaptation 1

• End-of-treatment PET-CT: Assess response and determine need for consolidation radiotherapy 1

Specific Toxicity Considerations:

• Bleomycin pulmonary toxicity: Occurs in 10-31% of patients, with higher rates after >2 cycles in elderly patients 3, 4
• Doxorubicin cardiotoxicity: Monitor for heart failure symptoms
• Vinblastine neuropathy: Assess for peripheral neuropathy at each visit
• Myelosuppression: CBC monitoring before each cycle

Common Pitfalls and Caveats

1. Do not exceed 2 cycles of bleomycin in patients >60 years - this is associated with unacceptable pulmonary toxicity rates 1

2. Do not omit interim PET after 2 cycles - this is essential for treatment adaptation and improved outcomes in both positive and negative responders 1

3. Avoid total bleomycin doses >400 units - pulmonary toxicity increases dramatically above this threshold 2

4. For lymphoma patients, administer test doses: Give 2 units or less for the first 2 doses due to anaphylactoid reaction risk 2

5. ISRT is preferred over IFRT - involved-site radiotherapy provides excellent disease control with reduced long-term toxicity compared to involved-field radiotherapy 1

6. Radiotherapy may be omitted in selected patients with negative interim PET when late radiation risks outweigh short-term disease control benefits, though this requires careful individualization as combined-modality treatment shows superior progression-free survival 1